These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8486957)

  • 21. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.
    Baxter R; Keshavan P; Welsch JA; Han L; Smolenov I
    Hum Vaccin Immunother; 2016 May; 12(5):1300-10. PubMed ID: 26829877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.
    Lieberman JM; Chiu SS; Wong VK; Partidge S; Chang SJ; Chiu CY; Gheesling LL; Carlone GM; Ward JI
    JAMA; 1996 May; 275(19):1499-503. PubMed ID: 8622225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
    Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
    Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single-dose antihelminthic treatment does not influence immunogenicity of a meningococcal and a cholera vaccine in Gabonese school children.
    Brückner S; Agnandji ST; Elias J; Berberich S; Bache E; Fernandes J; Loembe MM; Hass J; Lell B; Mordmüller B; Adegnika AA; Kremsner P; Esen M
    Vaccine; 2016 Oct; 34(44):5384-5390. PubMed ID: 27642131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.
    Block SL; Christensen S; Verma B; Xie F; Keshavan P; Dull PM; Smolenov I
    Vaccine; 2015 Apr; 33(18):2175-82. PubMed ID: 25744224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination.
    Mohammed I; Onyemelukwe GC; Obineche EN; Gupta N; Oyeyinka GO
    J Infect; 1984 Sep; 9(2):197-202. PubMed ID: 6438245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children.
    King WJ; MacDonald NE; Wells G; Huang J; Allen U; Chan F; Ferris W; Diaz-Mitoma F; Ashton F
    J Pediatr; 1996 Feb; 128(2):196-202. PubMed ID: 8636811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis for protection rate and antibody levels of epidemic cerebrospinal meningitis among children aged between 3-23 months in Liuzhou, in 2012].
    Cui XL; Wu X; Li MQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1079-1083. PubMed ID: 28057112
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
    Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
    Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response of children to Neisseria meningitidis polysaccharide vaccines.
    Monto AS; Brandt BL; Artenstein MS
    J Infect Dis; 1973 Apr; 127(4):394-400. PubMed ID: 4632878
    [No Abstract]   [Full Text] [Related]  

  • 32. The antimeningococcal vaccine VAMENGOC B-C induced poor serum and salivary antibody response in young Brazilian children.
    Carbonare SB; Arslanian C; Silva ML; Farhat CK; Carneiro-Sampaio MM
    Pediatr Infect Dis J; 1995 Sep; 14(9):797-803. PubMed ID: 8559631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody responses of human infants to three doses of group A Neisseria meningitidis polysaccharide vaccine administered at two, four, and six months of age.
    Gold R; Lepow ML; Goldschneider I; Draper TF; Gotschlich EC
    J Infect Dis; 1978 Dec; 138(6):731-5. PubMed ID: 105053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children.
    Gold R; Lepow ML; Goldschneider I; Draper TF; Gotshlich EC
    J Infect Dis; 1979 Nov; 140(5):690-7. PubMed ID: 118997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel.
    Zangwill KM; Stout RW; Carlone GM; Pais L; Harekeh H; Mitchell S; Wolfe WH; Blackwood V; Plikaytis BD; Wenger JD
    J Infect Dis; 1994 Apr; 169(4):847-52. PubMed ID: 8133100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.
    Borrow R; Goldblatt D; Andrews N; Richmond P; Southern J; Miller E
    J Infect Dis; 2001 Aug; 184(3):377-80. PubMed ID: 11443568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunological effectiveness of a dried group-A meningococcal polysaccharide vaccine].
    Alliluev AP; Kotel'nikova OV; Chernyshova TF; Skirda TA; Kuvakina VI
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Mar; (3):106-12. PubMed ID: 6428089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines.
    Lepow ML; Goldschneider I; Gold R; Randolph M; Gotschlich EC
    Pediatrics; 1977 Nov; 60(5):673-80. PubMed ID: 411104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.
    Fijen CA; Kuijper EJ; Drogari-Apiranthitou M; Van Leeuwen Y; Daha MR; Dankert J
    Clin Exp Immunol; 1998 Dec; 114(3):362-9. PubMed ID: 9844044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.